Charles River Announces New Business Alignment; Doesn't Expect Segment Reporting Change
Charles River Laboratories International, Inc. (NYSE: CRL) announced today a new business alignment which unifies its Research Models and Services and Preclinical Services businesses. This unification will enhance our ability to provide clients with a seamless and integrated portfolio of the essential products and services required to support their drug development programs.
James C. Foster, Chairman, President and Chief Executive Officer, said, “As our clients continue to transform their business models, we must evolve with them. Unifying these two businesses will improve client access to our extensive in vivo expertise and enable us to provide more flexible solutions to their drug development needs. These solutions can be structured either globally or regionally, depending on the clients' requirements. We believe this new business alignment will enhance our position as the world's premier early-stage contract research organization.”
“By strengthening the linkage between RMS and PCS, we lay the foundation for continued process improvement and enhanced operating efficiency across our portfolio,” Mr. Foster concluded.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.